Omnimmune Holdings, Inc. is engaged in the provision of cancer therapeutic, diagnostic and prognostic technologies. The company is headquartered in Houston, Texas and currently employs 2 full-time employees. The company went IPO on 2007-12-19. The firm is the holding company of Omnimmune Corp. Omnimmune has acquired licensed rights to diagnostic and platform monoclonal antibody technologies. Omnimmune’s hCGß and related technologies, which are protected through an expanding intellectual property portfolio, have been developed at institutions including Columbia University of New York, New York (Columbia), The Allegheny-Singer Research Institute of the West Penn Allegheny Health System, Pittsburgh, Pennsylvania (Allegheny) and The Institute Gustave Roussy, Paris, France (IGR).
Follow-Up Questions
Who is the CEO of Omnimmune Holdings Inc?
Travis McPhee is the Chief Executive Officer of Omnimmune Holdings Inc, joining the firm since 2007.
What is the price performance of OMMH stock?
The current price of OMMH is $0, it has decreased 0% in the last trading day.
What are the primary business themes or industries for Omnimmune Holdings Inc?
Omnimmune Holdings Inc belongs to Biotechnology industry and the sector is Health Care
